B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: A cohort study

Clinical Otolaryngology

Volumn 34, Issue 4, 2009, Pages 328-335

  Martinez Del Pero, M ^a   Chaudhry, A ^a   Jones, R B ^a   Sivasothy, P ^a   Jani, P ^a   Jayne, D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CHLORPHENIRAMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; B LYMPHOCYTE; BREAST CANCER; BREAST CARCINOMA; BRONCHUS INJURY; CHEST INFECTION; CLINICAL ARTICLE; COHORT ANALYSIS; DELAYED HYPERSENSITIVITY; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG SAFETY; EAR NOSE THROAT DISEASE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; EXTERNAL OTITIS; EYE DISEASE; FEMALE; FOLLOW UP; HAND SWELLING; HEAD AND NECK DISEASE; HEADACHE; HEART INFARCTION; HUMAN; INFECTION; KIDNEY FAILURE; LUNG INFECTION; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUTROPENIA; ORBIT GRANULOMA; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT INFECTION; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEROLOGY; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SWELLING; TERTIARY HEALTH CARE; THERAPY EFFECT; TONGUE CARCINOMA; TOTAL BIRMINGHAM VASCULITIS ACTIVITY SCORE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; PREDNISOLONE; RECURRENCE; RETREATMENT; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 68349157167     PISSN: 17494478     EISSN: 17494486     Source Type: Journal    
DOI: 10.1111/j.1749-4486.2009.01968.x     Document Type: Article

References (25)

1. Watts R., Lane S., Hanslik T. et al. (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 66, 222 227
2. Jayne D.R. Rasmussen N. (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin. Proc. 72, 737 747
3. Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488 498
4. White E.S. Lynch J.P. (2006) Pharmacological therapy for Wegener's granulomatosis. Drugs 66, 1209 1228
5. De Groot K., Rasmussen N., Bacon P.A. et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461 2469
6. Jayne D., Rasmussen N., Andrassy K. et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36 44 (Pubitemid 36765101)
7. WGET Research Group 2005) Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351 361
8. Lee R.W. D'Cruz D.P. (2008) Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs 68, 747 770
9. Walsh M., Chaudhry A. Jayne D. (2008) Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322 1327
10. Scott S.D. (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 6, 195 197
11. Aouba A., Pagnoux C., Bienvenu B. et al. (2008) Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin. Rev. Allergy Immunol. 34, 65 73
12. Keogh K.A., Wylam M.E., Stone J.H. et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 262 268
13. Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173, 180 187
14. Seo P., Specks U. Keogh K.A. (2008) Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J. Rheumatol. 35, 2017 2023
15. Aries P.M., Hellmich B., Voswinkel J. et al. (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 65, 853 858
16. Aries P.M., Lamprecht P. Gross W.L. (2006) Rituximab in refractory Wegener's granulomatosis: favorable or not? Am. J. Respir. Crit. Care Med. 173, 815 816 author reply 816
17. Hellmich B., Flossmann O., Gross W.L. et al. (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605 617
18. Fauci A.S. Wolff S.M. (1994) Wegener's granulomatosis: studies in eighteen patients and a review of the literature. 1973. Medicine 73, 315 324
19. Reinhold-Keller E., Beuge N., Latza U. et al. (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 43, 1021 1032
20. Smith K.G., Jones R.B., Burns S.M. et al. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970 2982
21. Omdal R., Wildhagen K., Hansen T. et al. (2005) Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 34, 229 232
22. Cheung C.M.G., Murray P.I. Savage C.O.S. (2005) Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br. J. Ophthalmol. 89, 1542
23. Specks U., Fervenza F.C., McDonald T.J. et al. (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44, 2836 2840
24. Stasi R., Stipa E., Del Poeta G. et al. (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45, 1432 1436
25. Wong C.F. (2007) Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol. Dial. Transplant. 22, 32 36